AstraZeneca has announced $3.5 billion of capital investment in the US focused on expanding the company’s research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment.  

AstraZeneca’s expanding footprint in the US includes, among others: 

• A R&D center in Kendall Square, Cambridge, Massachusetts; 

• A manufacturing facility for biologics in Maryland;  

• Cell-therapy manufacturing capacity on the West and East Coasts. 

• Specialty manufacturing in Texas. 

The company says that these US investments are the first of a series of steps to help it meet its goal to achieve $80 billion in total revenue by 2030, a goal set by the company earlier this year (May 2024). A key element of the company’s strategy is accelerating its development in the US. The US is AstraZeneca’s largest market, generating 44% of its total revenue. 

AstraZeneca has approximately 17,800 employees working across 17 R&D, manufacturing and commercial sites spanning 12 states in the US. With the new investments announced, the company says it expects to add more than a thousand jobs.  

The investments in the US are the latest expansions by the company. In May (Mayr 2024), the company announced plans to build a $1.5-billion manufacturing facility in Singapore for antibody drug conjugates (ADCs). The planned greenfield facility, supported by the Singapore Economic Development Board, will be AstraZeneca’s first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale. AstraZeneca aims to begin design and construction of the manufacturing facility by the end of 2024, with targeted operational readiness from 2029. 

Source: AstraZeneca